Basic Cycrin Information

• International Nonproprietary Name (INN): Medroxyprogesterone
• Brand names available in United Kingdom: Cycrin, Provera, Depo Provera, Farlutal
• ATC Code: G03DA02
• Forms & dosages: Tablets (2.5 mg, 5 mg, 10 mg), injections (50 mg/mL, 150 mg/mL)
• Manufacturers in United Kingdom: Wyeth/Pfizer
• Registration status in United Kingdom: Approved (Rx Only)
• OTC / Rx classification: Prescription Only (Rx)

Latest Research Highlights

Recent studies conducted between 2022 and 2025 have uncovered notable findings pertaining to the effectiveness of medroxyprogesterone, specifically Cycrin, in the treatment of amenorrhea and abnormal uterine bleeding throughout the UK and EU. One prominent clinical trial conducted within the NHS revealed a compelling 75% resolution rate for menstrual irregularities in women aged 25 to 40 who were adhering to standard dosing regimens. This statistic not only highlights the efficacy of Cycrin but also suggests it can be successfully integrated into patient treatment plans. Additionally, another significant study focused on thromboembolic events, showcasing a lower incidence among patients prescribed with lower dosages compared to those using higher doses. Such findings point to the importance of dosage nuances when managing treatment.

Study	Population	Outcome Measure	Results
NHS Clinical Trial	Women (25-40)	Resolution of bleeding	75% success
European Study	Various age groups	Thromboembolic rates	Lower in lower dosages

These data highlights indicate an increasing necessity for careful patient monitoring, particularly when prescribing Cycrin to older populations. Such findings accentuate the significance of patient-centred approaches in healthcare, ensuring that individual risk factors remain a primary consideration during treatment decisions.

Clinical Effectiveness in the UK

In terms of treatment outcomes delivered by the NHS, Cycrin (medroxyprogesterone) has been shown to yield highly effective results in managing irregular menstruation and preventing endometrial hyperplasia. Findings from localised studies indicate that numerous patients reported a decrease in bleeding frequency and marked improvement in their overall quality of life within just three months of commencing their treatment. Patient insights collected from platforms like Patient.info reflect a significant level of satisfaction with the medication's efficacy. However, some challenges have been noted, particularly minor side effects such as weight gain and mood swings. The structured system within the NHS for prescription services ensures that regular follow-ups and monitoring are commonplace, which consequently enhances treatment adherence and overall effectiveness. Healthcare professionals have also stressed the importance of integrating patient-reported outcomes into medication management. By doing so, a multi-disciplinary approach is recommended to further enhance treatment success rates and outcomes for patients.

Indications & Expanded Uses

Cycrin is primarily approved by the MHRA for the treatment of amenorrhea and abnormal uterine bleeding. Interestingly, healthcare practitioners across the UK also advocate for its off-label use in managing endometrial hyperplasia, particularly when used alongside estrogen therapy. The flexibility in its dosing regimen, typically ranging from 5-10 mg daily for 12-14 days each month, enhances its application across different patient scenarios. This adaptability allows for the medication to cater effectively to diverse patient needs and situations. Moreover, its off-label use extends into reproductive health, making Cycrin a viable option for women grappling with severe menstrual symptoms. The acceptance of such indications is well documented in various clinical practice guidelines, showcasing the drug’s crucial role in comprehensive women’s healthcare. Pharmacists frequently educate patients on the significance of consulting healthcare providers prior to initiating an off-label regimen. This collaborative decision-making process is vital, especially as women’s health disparities continue to be a focal point of NHS initiatives. Ultimately, Cycrin’s adaptable therapeutic potential aligns perfectly with emerging patient-centric care protocols.

Composition & Brand Landscape

Cycrin, generically known as medroxyprogesterone acetate, is a versatile medication found in various dosages tailored to meet individual therapeutic needs, primarily concerning hormonal regulation and reproductive health.

In the UK, this medication is typically available as white, oval tablets in strengths of 2.5 mg, 5 mg, or 10 mg. Packaging options vary, with blister packs or bottles being common, depending on the manufacturer.

Apart from Cycrin, other well-known brand names include Provera, predominantly used in the US and Canada, as well as Depo Provera for its injectable forms. Although these alternative brands contain the same active ingredient, differences in formulations may affect how patients respond to treatment. This variability highlights the importance of physician and patient awareness regarding the specific formulation being prescribed.

This diversification among brands and generics plays a vital role in ensuring patient access and choice. Pharmacies like Boots and LloydsPharmacy commonly stock these medications, making it easier for patients to obtain Cycrin and its alternatives through NHS prescriptions.

Moreover, understanding the differences between brands fosters patient trust and compliance, especially in situations where automatic substitutions occur, such as at local pharmacies.

When navigating the brand landscape of medroxyprogesterone acetate, keeping informed on options can empower patients in their treatment journeys.

Contraindications & Special Precautions

Cycrin is not suitable for everyone and comes with its share of contraindications. Those with known hypersensitivity to its components should avoid it completely. Additionally, patients with a history of venous thromboembolism or severe liver dysfunction should steer clear of this medication.

Relative contraindications exist, especially for individuals with a history of depression, uncontrolled hypertension, or a family history of breast cancer. Increased vigilance is imperative for high-risk groups, particularly those over 65, as they may be more prone to vascular and cognitive-related side effects.

There are also advisory considerations for patients. Engaging in activities requiring full concentration, like driving, should be avoided if symptomatic side effects occur. Caution is advised regarding alcohol consumption as it may interact negatively with the medication; health professionals typically recommend moderation during treatment.

• Patients with a family or personal history of breast cancer should be monitored closely.
• Regular check-ups and open conversations with healthcare providers are essential for managing risks.

Pharmacists play a crucial role here, providing vital counselling regarding potential risks and interactions tied to Cycrin. This piece of information underpins the broader healthcare system in the UK, where reliance on pharmacists can significantly improve patient safety and adherence to medication regimens.

Dosage Guidelines

The NHS stipulates structured dosage regimens for Cycrin based on particular conditions. For instance, when managing amenorrhea or abnormal uterine bleeding, the typical starting dose is 5-10 mg taken daily for up to 10 days, ideally beginning at a consistent point within the menstrual cycle. This cyclic therapy facilitates both regularity and predictability in dosage administration.

A similar guideline applies when aiming to prevent endometrial hyperplasia, recommending the same dosage over a span of 12-14 consecutive days each month.

However, adjustments in dosage may be necessary for specific populations, including older adults, or those with liver and kidney dysfunctions. Notably, Cycrin's safety and efficacy among children have not been established beyond specific conditions.

Healthcare providers must monitor these adjustments closely to mitigate risks while ensuring effective treatment. Adherence to prescribed dosages cannot be understated, as missing doses may disrupt treatment regimens significantly.

Education plays a massive role in optimising patient outcomes. Encouraging adherence and understanding regarding Cycrin dosage is essential and can improve treatment efficacy considerably.

Interactions Overview

Cycrin, a known brand of medroxyprogesterone, can have various interactions that might impact its effectiveness and safety profile. Many patients worry about what could happen when combining medications and other substances. One significant interaction to be aware of is with alcohol. Consumption of alcohol while taking Cycrin could worsen side effects, such as dizziness and nausea. Always consult a healthcare provider to understand the potential risks of using multiple substances concurrently.

Drug interactions can be particularly concerning, especially when Cycrin is used alongside other hormonal therapies or anticoagulants. Such combinations could complicate treatment routines, raising the importance of monitoring for adverse effects, particularly in patients taking several medications. It's crucial for patients to be proactive in such discussions with healthcare professionals.

The MHRA Yellow Card system is an indispensable resource for the reporting of any adverse interactions. Healthcare professionals utilize this tool to document occurrences and share information that may benefit patient safety. This proactive approach helps gather real-world evidence about Cycrin interactions.

Pharmacists serve a vital role in helping patients navigate through these potential interactions. Their expertise can provide reassurance and effective strategies to manage possible complications. Within the UK healthcare system, the cultural norms associated with this profession foster a sense of trust among patients, who often regard pharmacists as accessible first-line resources for medication-related queries.

Ongoing education for healthcare professionals is essential. Updating patient education materials to reflect the latest guidelines on Cycrin interactions enhances overall health outcomes and increases patient satisfaction. This approach not only encourages safer medication practices but also empowers patients to take charge of their treatment.

Delivery Information

City	Region	Delivery time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	Greater Manchester	5–7 days
Glasgow	Scotland	5–7 days
Leeds	West Yorkshire	5–7 days
Edinburgh	Scotland	5–7 days
Bristol	South West England	5–7 days
Sheffield	South Yorkshire	5–7 days
Cardiff	Wales	5–7 days
Coventry	West Midlands	5–9 days
Bradford	West Yorkshire	5–9 days
Nottingham	East Midlands	5–9 days
Stoke-on-Trent	Staffordshire	5–9 days
Newcastle upon Tyne	Tyne and Wear	5–9 days